Cardiovascular Journal of Africa: Vol 26 No 2 Supplement (March/April 2015)

AFRICA

S55

CVJAFRICA • Volume 26, No 2, H3Africa Supplement, March/April 2015

pathophysiology, and management.

Am J Hematol

2008;

(1): 63–70.

36.

Aliyu ZY

Suleiman A

Attah E

et al

. NT-proBNP as a marker of

cardiopulmonary status in sickle cell anaemia in Africa.

Br J Haematol

2010;

150

(1): 102–107.

37. Cox SE, Soka D, Kirkham FJ,

et al

Tricuspid regurgitant jet veloc- ity and hospitalization in Tanzanian children with sickle cell anemia.

Haematologica

2014;

(1): e1–4.

38. Arlet JB, Ribeil JA, Chatellier G,

et al

Determination of the best method to estimate glomerular filtration rate from serum creatinine in adult patients with sickle cell disease: a prospective observational cohort study.

BMC Nephrol

2012;

: 83.

39. Iwalokun BA, Iwalokun SO, Hodonu SO, Aina OA, Agomo PU.

Evaluation of microalbuminuria in relation to asymptomatic bacteruria in Nigerian patients with sickle cell anemia.

Saudi J Kidney Dis Transpl

2012;

(6): 1320–1330.

40. Adedoyin OT, Adesiyun OO, Adegboye OA, Bello OA, Fatoye OP.

Sickle cell nephropathy in children seen in an African hospital – case report.

Niger Postgrad Med J

2012;

(2): 119–122.

41. Osei-Yeboah CT, Rodrigues O.

Renal status of children with sickle cell disease in Accra, Ghana.

Ghana Med J

2011;

(4): 155–160.

42. Pakasa NM, Sumaïli EK.

[Pathological peculiarities of chronic kidney disease in patient from sub-Saharan Africa. Review of data from the Democratic Republic of the Congo].

Ann Pathol

2012;

(1): 40–52.

43. Driscoll MC, Hurlet A, Styles L,

et al

Stroke risk in siblings with sickle cell anemia.

Blood

2003;

101

(6): 2401–2404.

44. Kwiatkowski JL, Hunter JV, Smith-Whitley K, Katz ML, Shults J,

Ohene-Frempong K. Transcranial Doppler ultrasonography in siblings

with sickle cell disease.

Br J Haematol

2003;

121

(6): 932–937.

45. Flanagan JM, Frohlich DM, Howard TA,

et al

. Genetic predictors

for stroke in children with sickle cell anemia.

Blood

2011;

117

(24):

6681–6684.

46. Platt OS, Brambilla DJ, Rosse WF,

et al

Mortality in sickle cell disease. Life expectancy and risk factors for early death.

N Engl J Med

1994;

330

(23): 1639–1644.

47. Genovese G, Friedman DJ, Ross MD,

et al

. Association of trypanolytic

ApoL1 variants with kidney disease in African Americans.

Science

2010;

329

(5993): 841–845.

48.

Ashley-Koch AE, Okocha EC

Garrett ME,

et al

MYH9

and

APOL1

are both associated with sickle cell disease nephropathy.

Br J Haematol

2011;

155

(3): 386–394.

49.

Desai AA,

Zhou T

Ahmad H,

et al

. A novel molecular signature for

elevated tricuspid regurgitation velocity in sickle cell disease.

Am J Respir Crit Care Med

2012;

186

(4): 359–368.

50.

Elira Dokekias A,

Okandze Elenga JP

Ndinga J

Sanogo I

Sangare A.

[Evaluation of clinical response by hydroxyurea in 132 patients with

major sickle cell anemia].

Tunis Med

2005;

(1): 32–7.

51. Mellouli F, Bejaoui M.

[The use of hydroxyurea in severe forms of sickle cell disease: study of 47 Tunisian paediatric cases].

Arch Pediatr

2008;

(1): 24–28.

52.

Wonkam A

Ponde C

Nicholson N

Fieggen K, Ramessar R, Davidson A

. The burden of sickle cell disease in Cape Town.

S Afr Med J

2012;

102

(9): 752–754.

53. Makubi A, Soka D, Makani J. Moyamoya disease, a rare cause of recur-

rent strokes in an african sickle cell child: does hydroxyurea have a role

in this context?

Int J Child Health Nutr

2012;

: 82–85.

54. Ware RE.

Hydroxycarbamide: clinical aspects.

Comptes Rendus Biol

2013;

336

(3): 177–182.

55.

Olabode JO

Shokunbi WA

. Types of crises in sickle cell disease patients

presenting at the haematology day care unit (HDCU), University

College Hospital (UCH), Ibadan.

West Afr J Med

2006;

(4): 284–288.

56. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ.

Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea.

Blood

1997;

(3):

1078–1088.

57.

Wang WC

Ware RE

Miller ST

et al

. Hydroxycarbamide in very young

children with sickle-cell anaemia: a multicentre, randomised, controlled

trial (BABY HUG).

Lancet

2011;

377

(9778): 1663–1672.

58. Wonkam A, Mba CZ, Mbanya D,

et al

Psychosocial burden of sickle cell disease on parents with an affected child in Cameroon.

J Genet

Couns

2014;

(2): 192–201.

59. H3Africa Consortium.

Research capacity. Enabling the genomic revolu- tion in Africa.

Science

2014;

344

(6190): 1346–1348.

60.

Peprah E

Xu H, Tekola-Ayele F

Royal CD

. Genome-wide association

studies in Africans and African Americans: Expanding the framework

of the genomics of human traits and disease.

Public Health Genom

2015;

(1): 40–51.

61.

Lambert CA

Tishkoff SA

. Genetic structure in African populations:

implications for human demographic history.

Cold Spring Harb Symp Quant Biol

2009;

: 395–402.

62. Gurdasani D, Carstensen T, Tekola-Ayele F,

et al

The African Genome Variation Project shapes medical genetics in Africa. Nature

2015;

517

(7534): 327–332.

63.

Kappler-Gratias S

Auxerre C

Dubeaux I,

et al

. Systematic RH geno-

typing and variant identification in French donors of African origin.

Blood Transfus

2014;

(Suppl 1): s264–272.

64.

Dandara C

Swart M,

Mpeta B

Wonkam A,

Masimirembwa C

Cytochrome P450 pharmacogenetics in African populations: implica-

tions for public health.

Expert Opin Drug Metab Toxicol

2014;

(6):

769–785.